LYEL Latest Press Releases

-- November 4, 2026 --

Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2026 Globe Newswire 4:05 PM

Lyell Immunopharma Announces $80 Million Private Placement to Advance Ronde-Cel Toward Planned BLA Submission Globe Newswire 9:02 AM

Lyell Immunopharma to Present Positive Updated Ronde-Cel Data in More than 80 Patients at ASH 2026 from PiNACLE Pivotal Trial in 3L+ and from Phase 1/2 2L Cohort in Patients with Relapsed/Refractory Large B-Cell Lymphoma Globe Newswire 9:01 AM

-- November 2, 2026 --

Lyell Immunopharma To Participate in November Investor Events Globe Newswire 8:00 AM

-- September 14, 2026 --

Lyell Immunopharma To Participate in the Baird 2026 Global Healthcare Conference Globe Newswire 7:00 AM

-- September 10, 2026 --

Lyell Immunopharma Completes Manufacturing Transfer for LYL273 and Provides Updated Timeline on Phase 1/2 Trial in Metastatic Colorectal Cancer Globe Newswire 4:05 PM

-- August 6, 2026 --

Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2026 Globe Newswire 4:05 PM

-- June 25, 2026 --

Lyell Immunopharma Announces Participation in H.C. Wainwright 4th Annual Cell Therapy Virtual Conference Globe Newswire 8:00 AM

-- June 12, 2026 --

Lyell Immunopharma Presents Updated Safety Data and Translational Insights for Rondecabtagene Autoleucel (Ronde-Cel) in Patients with Large B-Cell Lymphoma at European Hematology Association 2026 Congress Globe Newswire 12:45 PM

Market Data Delayed 15 Minutes